Join thousands of traders sharing insights, catalysts, and charts.
Join thousands of traders sharing insights, catalysts, and charts.
Yes and No.
I checked and I had ignored on for myself but I never did it.
I turned it off and fixed the problem went away.
Very Weird - not sure who else but me could change the ignore setting.
So weird . . . late yesterday I all of sudden couldn't see my posts on the IHUB message board.
They hadn't been removed by the admin, I just could see them. They were still there.
I tried using a different browser and could see them when I wasn't logged in but as soon as I logged in the were gone.
I rebooted my laptop and then waited until this morning to see if it was an IHUB issue but problem remained.
I then started looking through my settings and finally discovered that for some reason I was now configured to ignore myself.
I have never ignored anyone so have no clue how this happened.
Anyway once I unignored myself I could then see the messages again.
Just posting this incase anyone else runs into this problem.
Wouldn't that presume that spoofing has been going on Survivor?
That is yet to be proven.
I warned you . . . the Big Money Rat Bastards are not going to make this easy smile
Reposting because this message is no longer visible on the main NWBO board but also doesn't appear to have been removed.
This is a new one . . . very wierd
I warned you . . . the Big Money Rat Bastards are not going to make this easy ![]()
Bought my first shares December 9, 2013 and have buying ever since.🚀
I moved money into my Roth yesterday and was staring a 27 cents thinking I should wait it will go down again . . . and now at 32 cents not sure what to do.
I have a feeling the Big Money Rat Bastards will manipulate it lower again . . . unless of course we really get approval this week. Hard to say. The Brits usually take a long Christmas holiday so I don't expect this back at full force this week but one never know.
Good Luck Longs . . . I think the moment we have been waiting for will be here soon.
The real question is can the Big Money Rat Bastards still force the NWBO stock price down even after approval. They have done it before on good news. Remember this? They just through 77 million shares naked or real at it. They can do that again.

Not really following you???
What exactly is not going my way?
Jeeze, you know "Trade Secrets" protect NWBO by keeping secret critical info on making DCVAX-L.
Relative to newer patents there is protection there too.
Per AI
Northwest Biotherapeutics (NWBO) has newer patents and in-licensed technologies (like in June 2024) that enhance their dendritic cell (DC) therapies, potentially strengthening IP around DCVax-L and related products by covering improved DC versions, manufacturing, and tumor microenvironment approaches, but these aim to protect their product development, not prevent others from using their licensed tech for NWBO's own use.
Key IP Developments for NWBO:
2024 In-License: In June 2024, NWBO announced licensing new patents filed in 2023 covering advanced DC-based therapies, conditioning regimens, and reprogramming tumor environments, adding significant new IP life to their portfolio.
Existing IP: NWBO already holds patents and pending applications for its DCVax products, including manufacturing processes, in various jurisdictions like Japan.
DCVax-L vs. DCVax-Direct: Their products, including DCVax-L (from tumor lysate) and DCVax-Direct (injecting cells directly into tumors), use patent-protected methods to mature dendritic cells.
How This Relates to DCVax-L:
These newer patents bolster NWBO's intellectual property around dendritic cell technology, which underpins DCVax-L.
They aim to protect NWBO's innovations and market position for their own DC-based vaccines, rather than restrict NWBO's ability to develop or use DCVax-L itself.
In essence, NWBO's patent strategy focuses on expanding and securing their own technological advantage in the dendritic cell space, including for their DCVax-L product line, through new filings and licensing.
Some more on NWBO patent protection and other protects afforded NWBO.
Yes, other forms of legal protection beyond standard patents may prevent competitors from using Northwest Biotherapeutics' (NWBO) DCVax technology, primarily through regulatory exclusivity and potentially trade secrets.
Regulatory Exclusivity
Regulatory exclusivity is a separate form of protection granted by government regulatory bodies like the FDA in the U.S. or the EMA in Europe, provided specific criteria are met. It bars competitors from obtaining marketing approval for the same drug for a set period, regardless of patent status.
Orphan Drug Exclusivity (ODE): This is a key potential protection for DCVax-L, which is used for brain cancer (glioblastoma multiforme), a rare disease. If the drug receives FDA approval with an Orphan Drug Designation, it is generally entitled to a seven-year market exclusivity period in the U.S.. In Europe, this period is typically ten years.
Data Exclusivity: Regulatory authorities require the original applicant to submit extensive data from preclinical and clinical trials. Data exclusivity prevents subsequent applicants from relying on this data to support their own marketing applications for a specified period (e.g., five years for a new chemical entity in the U.S.), forcing them to conduct their own expensive and time-consuming trials.
Trade Secrets
NWBO may also protect certain aspects of its technology, such as specific manufacturing processes (like the Flaskworks system for a closed manufacturing process), as trade secrets. Unlike patents, which require public disclosure of the invention, trade secrets rely on keeping information confidential. This protection can theoretically last indefinitely as long as the information remains secret and reasonable efforts are made to maintain its confidentiality.
In summary, NWBO employs an integrated strategy for intellectual property protection that combines a substantial patent portfolio with other mechanisms, such as seeking Orphan Drug status, to protect its technology from competitors.
Yes, Northwest Biotherapeutics' (NWBO) DCVax technology is protected by a portfolio of patents. These patents cover various aspects, including manufacturing processes, the composition of the therapy, and methods of use.
The duration of protection varies by individual patent, but generally, a U.S. utility patent provides exclusive rights for 20 years from its filing date.
Key details regarding NWBO's patent portfolio:
Multiple Patents: NWBO has an integrated strategy involving numerous issued patents and many more pending in the U.S. and internationally.
Broad Coverage: The patents cover the use of dendritic cells in specific DCVax products, unique manufacturing processes (including automation), and methods for producing more potent dendritic cells.
Recent Additions: In June 2024, NWBO announced an exclusive license for an additional portfolio of dendritic cell technologies, which includes five new patent families filed in 2023. These newly filed patents have their full potential patent life ahead of them (up to 2043).
Patent Expirations: Specific patent expiration dates vary. For example, one patent mentioned in a third-party analysis (US8673893) has an expiration date in July 2028, but this is only one of many patents in their portfolio. The company has consistently asserted its "freedom to operate" regarding other parties' patents.
The company actively manages its intellectual property to ensure robust protection and the ability to scale up manufacturing of its DCVax products.
Sounds like NWBO DCVAX patent infringement.
Even if DOC 1021 is a "Double Loaded" dendritic cell vaccine has additional steps it as to the process to incorporate more lysate it means it is an enhancement to NWBO's patents not a completely new invention so the would have to pay NWBO to license their already patented steps or NWBO can simply prevent them from producing it.
If you don't believe me here is what AI has to say about it:
Yes, you can patent an improvement, but the original patent owner still owns their original patent and you'd likely need their permission (a license) to sell your improved product because it incorporates their patented invention; you'll have your own patent for the improvement, but they have rights to the base technology, creating a situation where both parties might need licenses from each other.
How it Works
Your Improvement is Patentable: If your improvement is novel, useful, and non-obvious, you can get your own patent (a "improvement patent") for the new features you added.
Infringement Risk: You cannot legally make, use, or sell your improved product without a license from the original patent holder if your invention still uses the core elements of their existing patent.
Cross-Licensing: The original owner can't make or sell your improved version without a license from you (for your improvements), and you can't sell it without a license from them (for the base invention). This often leads to cross-licensing agreements.
Your Patent Covers the Difference: Your patent protects the new, improved parts, not the entire original invention.
Not sure why you feel the Nov 20th press release is so misleading Flip given the 2 foot issue due to modifications to the 2 engineers made to the system. It could be that they indeed that the construction activities did begin as stated and that is when the discovered the 2 foot issue. That construction could have then been halted while the decided what to do to resolve it. That then resulted in a delay in resuming the construction until January using a simplified design as stated at the ASM. All else the 6 months, the 2X, 2Q is delayed until 3Q still seem consistent with the PR. I don't know what I am saying is true since I am simply guessing and trying to tie the pieces together.
Press Release
20 NOV 2025
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
BETHESDA, Md., November 20, 2025 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out the construction of the first Grade C manufacturing suite in the Company’s Sawston, UK facility, the construction firm is onsite and the construction activities have begun. The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined. As such, the Company considers the construction of the first Grade C suite a major step towards potential large scale-up of the Company’s production of DCVax® products.
Manufacturing of medical products such as DCVax must be done in clean room facilities in sterile conditions. When manufacturing equipment and procedures involve steps open to the air, the manufacturing must take place in Grade B suites with special air handling and other requirements which are extremely expensive both to develop and to operate. In addition, only one patient’s product may be made in a Grade B suite at a time, and the whole suite must stop activity and be specially cleaned in between manufacturing one patient’s product and the next. The manufacturing of living cell products in general has traditionally had to be conducted in Grade B suites.
When a medical product is able to be manufactured using closed equipment and procedures that are not open to the air, the manufacturing can be conducted in Grade C manufacturing suites which are much less onerous and expensive to operate. In addition, multiple or numerous patient products may be manufactured simultaneously in a single Grade C manufacturing, and only certain equipment (not the whole suite) must be cleaned between production batches. These differences can enable a major increase in throughput and capacity, together with efficiency gains in both staff and materials. As the Company has previously reported, the Flaskworks system is specially designed to carry out the key manufacturing processes for DCVax-L products on a closed basis. Developing this system was particularly challenging because the DCVax-L manufacturing process includes the dendritic cells adhering like barnacles to the flasks containing them, and then the mature activated cells being harvested by detaching them without damaging or destroying them. The Company views use of the
Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites rather than Grade B suites – and the Company views such transition to Grade C suites as central to large scale-up of production.
The Company’s business plan currently envisions manufacturing being established in the Grade C suite in the Sawston facility during Q2 of next year, with the construction of the Grade C suite taking approximately 6 months, followed by equipment installation and validation. As previously reported, Advent worked closely with construction and engineering experts to develop a design and location within the Sawston facility that is expected to enable this first Grade C manufacturing suite to be constructed on a simplified basis at significantly lower construction costs and faster timeline. The project will also involve several million pounds of equipment costs.
For example, as noted in the Company’s recent 10-Q report, the cost to purchase certain fundamental equipment new is about £800,000 (approximately $1 million) per machine. Fortunately, Advent has been able to secure some of the machines at reduced cost. Due to long lead times, the Company is necessarily already proceeding with certain equipment purchases now. “We are excited to be under way with the construction activity and equipment sourcing for the first Grade C lab in our Sawston facility,” commented Linda Powers, the Company’s CEO. “We view this as a transformative step in our progress toward large scale operations.”
From the ASM transcript:
earlier this year, that we had developed a plan for a simplified C lab to build one on a simplified basis in a different location. It actually happens to be adjacent to the quarantine storage and loading docks, where far less infrastructure work has to be done, and it cut to less than half the cost of the design of the original C lab.
That's the one where we mentioned in our most recent quarterly report, Q3, that the contractor has already been selected and engaged, already been on site doing the prep work of the site, and we currently anticipate that the physical construction work would get underway at some point by the end of January for that, and then would be around a six-month timeframe to get finished for that.
No she was clearly falling on he sword admitting they screwed up and it caused delays.
I was mainly just responding to x that they need to clarify if this is just for GBM or for other solid tumor cancers too.
Yes agreed. I am glad they clarified this.
Not following you zadie.
I didn't hear this discussed today at least that I picked up on.
Can you explain in more detail - Thanks
They did not reveal what they hoped to achieve with the extra 2 feet hankman. That would have been interesting to hear.
This was an interesting and unexpected statement from today ASM
Lastly on the clinical is compassionate use. Our compassionate use program is ongoing. We have a steady stream of inquiries and requests that come in. We're in the process now of expanding to additional doctors. A number of doctors have become interested, and we're also in exploratory discussions with a private hospital chain that has numerous locations.
In the new year, we currently plan to offer compassionate use treatments for most types of solid tumor cancers, not just brain cancer, thanks to the expertise and the interest of these additional doctors. And we also are planning at a certain point to offer DCVax-Direct in addition to DCVax-L for compassionate use. So that will be a very important progression of our compassionate use program.
I agree there is no excuse for not having someone closely monitoring what the 2 engineers did that added 2 feet to the system. Unless they were plants deliberately trying to sabotage the project one would have to believe that they felt like they were doing something good so at minimum the requirements for the system (e.g. maximum dimensions) where not made to clear to them. It should have been. It is definitely a problem with the business model they have chosen where there are only a small number of NWBO employees employed by NWBO directly and the rest are consultants. It may seem like you are saving money but the reality looks like it is costs you in time (and money because it take longer) and in this case in understanding the objectives.
They also ran into an issue wherethe first 2 engineers re-engineered Flaskworks system making it 2 feet longer without being asked to do that which resulted in it no long fit the foot print so they had to bring in 2 new engineers to do the work instead. That may have been part of the delay.
Very informative ASM. It was well worth listening to Linda.
Here is a very very quick summary for anyone who missed it.
Linda gave a very good appreciation for the huge complexity, huge time expenditures and huge cost associated with every part of what they are doing (e.g. MRHA, Direct transition and ready to go (but spending money on manufacturing expansion vs Direct phase-2 first), Reading B-suites for commercialization, Getting C-suites up and running for future manufacturing simplification and capacity improvements including a simplified C-suite,
Clarified that they are focused on getting through MRHA for approval as their primary most important goal and then other focus areas will spring from MRHA approval.
Clarified that if and when approved they will use B-suites systems to manufacture DCVAX-L
From readying many of the posts on the board it is clear that many do not appreciate the huge expenses the must incur (e.g. $12 million on consultant for MRHA, $100 million on patents, $1 million for each piece of C-suite equipment with lead time well over a year, just to name a few).
They also run into issue like the first 2 engineers re-engineered Flaskworks systems making it 2 feet longer without being asked to do that which resulted in it no long fit the foot print so they had to bring in 2 new engineer to do the work instead.
Advent is wholly owned by NWBO clarification.
Additional 900 million shares are for flexibility not to just issue willy-nilly in short order. Focus will be non-delutive,
Expanding compassionate use including using DCVAX for other non-GBM cancers. They will be staring combo trials including Ovarian Cancer trial. There may be a new regional partnership in near future (not yet firm).
They also have a boat load of consultants that have been working with then for years that will join the management team immediately if and when they get approval.
I submitted some questions although doubt they will answer any of these. Thanks for the link beartrap
Hi I am XXXXXXXXXXX a long time investor in NWBO.
I have the following questions I would like to submit for discussion at the ASM.
(1) Is MHRA approval expected soon and why has it taken so long?
(2) Is approval anticipated only for DCVAX-L for GBM or will it be for DCVAX-L for other solid tumor cancers as well?
(3) I thought NWBO had announced that DCVAX-Direct phase-3 was going to start earlier in 2025. It has not yet started so is it going to happen and when?
(4) How much longer is it going to take to have Flaskworks fully automated closed system manufacturing approved, on-line and operational? Are we still working out some issues with functionality and when would we hope to submit it for approval?
That is probably enough tough questions that may be difficult to answer.
Merry Christmas and Thanks
XXXXXXXXXX
Has anyone gotten a link so us stockholders can hook in remotely to this to the ASM on the 29th? Thanks
Yes so true. Targeting one or even several cancer antigens is never going to cut it. We have seen other treatments that do this, not with a toxic payload, but just by activating our immune system to target these select antigens. What typically happens is there will be some initial improvement but then the cancer returns with vengeance as it mutates into a form without those select antigens. Now if they had some type of process like DCVAX that targets the full spectrum of cancer antigens that they could tune for each patient then they might have something . . . but not seeing how they could do that. GOOD LUCK & Merry Christmas Flip!!! Hopefully we will be getting new on approval soon soon.
What point is that??? . . . What exactly do you think more executives will accomplish???
More executives will do nothing to stop the Big Money Thugs that have been doing everything they can to stop NWBO and DCVAX.
Will more executives stop the naked shorting and spoofing and other manipulation aimed at keeping the NWBO stock price low?
If you believe that I have a bridge I'd like to sell you.
The C-Suite for Northwest Biotherapeutics (NWBO) is led by Linda F. Powers, who serves as Chairman, President, CEO, and CFO, with key scientific leadership from Dr. Alton L. Boynton as Chief Scientific Officer, alongside Marnix L. Bosch as Chief Technical Officer, all driving their mission in personalized cancer vaccines.
Key Executives:
Linda F. Powers: Chairman, President, CEO, and Chief Financial Officer (CFO).
Dr. Alton L. Boynton: Chief Scientific Officer (CSO) and Secretary.
Marnix L. Bosch: Chief Technical Officer (CTO).
This leadership team guides Northwest Biotherapeutics in developing its personalized immune therapies for solid tumors, known as DCVax®
That is inaccurate Smitty. Just ask AI.
Northwest Biotherapeutics (NWBO) is expanding its manufacturing capacity in the UK and has been hiring staff for its Sawston facility. In March 2021, the company announced it had hired 30 people and potentially another 150 for its Sawston, UK facility. As recently as November 2025, NWBO engaged a construction firm to expand its UK facility to increase production of its DCVax products.
Key developments in the UK manufacturing efforts:
* Facility expansion: In November 2025, NWBO announced the start of construction on the first Grade C manufacturing suite at its Sawston facility to significantly increase production capacity for its DCVax products.
* Initial staffing and training: As of March 2021, the company had hired and trained an initial team of 30 technical managers, scientists, and operators for its first production suites. Recruitment efforts were ongoing at the time.
* Manufacturing license: In December 2021, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved a license for GMP (clinical grade) manufacturing at the Sawston facility. This allowed the company to begin manufacturing DCVax-L products there.
Production commencement: By February 2022, the first vaccine production for a compassionate use patient with glioblastoma had begun at the Sawston facility.
* Automated manufacturing: NWBO is refining its manufacturing process, including the development of its automated Flaskworks system, which could eventually lead to larger-scale production. The company closed its smaller GMP facility in London and reallocated resources to the Sawston facility in October 2025.
AI disagrees with you.
Northwest Biotherapeutics (NWBO) SEC filings include "equivalency studies" as a risk factor, noting that changes in manufacturing methods could necessitate such studies or additional clinical trials. However, recent filings indicated no regulatory friction regarding "comparability" during the review process for its Marketing Authorization Application. You can find NWBO's official SEC filings through the SEC's EDGAR database.
Great write up. Right on the mark. Thanks for posting it Eagle!!!
There's plenty of evidence.
Citadel LLC and Citadel Securities LLC do not publish a specific "annual report failure to deliver" document. Failure to Deliver (FTD) data for individual firms like Citadel is generally not available in their public financial statements or annual reports.
Instead, information regarding Citadel's FTDs and related violations is found in regulatory filings, press releases from agencies such as the SEC and FINRA, and disciplinary action reports.
Key findings related to Citadel and failures/misreporting include:
Regulatory Fines: Citadel Securities has been fined multiple times by regulators for various reporting failures and other violations.
Recent Reporting Violations: In October 2024, FINRA fined Citadel Securities $1 million for failing to timely and accurately report data for tens of billions of equity and option order events to the Consolidated Audit Trail (CAT) repository between June 2020 and August 2024.
Prior Reg SHO Violations: In September 2023, the SEC charged Citadel Securities with violating Regulation SHO (which governs short sales) due to a coding error that caused millions of orders to be incorrectly marked as "long" or "short" over a five-year period (2015-2020), resulting in a $7 million penalty.
General FTD Data: The official SEC FTD data is published in a raw format and does not identify the specific firms responsible for the fails. The data is cumulative and reported for the market as a whole, not broken down by individual firm in public reports.
Thanks for posting this PGSD.
AI Overview
New MHRA/NICE Collaboration - Pharmacy Consulting
The main difference is that the MHRA (Medicines and Healthcare products Regulatory Agency) is responsible for authorizing medicines and devices for sale in the UK based on safety and effectiveness, while NICE (National Institute for Health and Care Excellence) evaluates whether those medicines are a good value for money for the NHS. The MHRA's role is regulatory, ensuring the product is safe and works, whereas NICE's role is advisory, assessing clinical and cost-effectiveness to recommend if it should be used on the NHS.
Medicines and Healthcare products Regulatory Agency (MHRA)
Role: The MHRA grants marketing authorizations for medicines and medical devices.
Focus: It ensures that products are safe, high-quality, and effective.
Authority: It is an executive agency of the Department of Health and Social Care.
National Institute for Health and Care Excellence (NICE)
Role: NICE provides guidance on the clinical and cost-effectiveness of new drugs and technologies.
Focus: It evaluates whether a medicine offers good value for the money spent by the NHS.
Authority: It is an executive non-departmental public body of the Department of Health and Social Care.
How they work together
Historically, NICE would issue guidance after the MHRA had already authorized a product.
The two organizations now have initiatives to work more closely, including pilot programs for concurrent reviews, to speed up patient access to new medicines by making decisions on safety and value at the same time.
This new, aligned approach aims to reduce the time it takes for new treatments to become available to patients on the NHS
If they get it below 17 cents again I am ready to buy again
You are speaking as if the price is normal fair market forces.
That is not what is going on here.
The prices is stuck in this range due to the Big Money Rat Bastards behind the scenes manipulating the price, spoofing and other methods to hold the price down.
What the trading patterns closely. Anytime the price starts to tick up money or naked shares are thrown at it to force it back down.
Why do you think there are all these paid doomsayers without any investment in NWBO continuously posting?
Do you really think they are just here to save us Longs from a doomed investment?
Big Pharma is scared sh!tl3ss over NWBO and the DCVAX technology eroding chemo drug profits.
The annual global revenue for the oncology drugs market was about $201.75 billion in 2023, but this figure includes more than just chemotherapy, encompassing targeted therapies, immunotherapies, and more. The global market for all oncology drugs is projected to reach over $518 billion by 2032, growing at an 11.3% compound annual growth rate (CAGR).
4:30 Pacific it 7:30 Eastern
We all knew deep down that that has been what is going on with the FDA but really pisses me off hearing it first hand from someone who experienced it.
Linda should reach our to RFK directly.